Sector News

Novo Nordisk in bid for Global Blood Therapeutics -sources

March 9, 2017
Life sciences

Danish drugmaker Novo Nordisk has approached Global Blood Therapeutics, a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.

The approach comes as Novo Nordisk seeks to shore up declining sales from its aging diabetes franchise. With its suite of blood disease treatments under development, Global Blood Therapeutics would be a boon to Novo Nordisk’s portfolio.

Global Blood Therapeutics is now working with an investment bank to review its options, and there is no certainty that it will enter into negotiations with Novo Nordisk or that it will explore a sale, the people said this week.

The sources asked not to be identified because the matter is confidential. Global Blood Therapeutics and Novo Nordisk declined to comment.

Global Blood Therapeutics shares rose as much as 32 percent on the news, and were trading up 15 percent at $32.45 in late morning trading in New York on Wednesday, giving the San Francisco-based company a market capitalization of around $1.4 billion. Novo Nordisk shares were down 1 percent.

Novo Nordisk has eschewed acquisitions in the past, as it focused on building its market-leading position in supplying insulin and other treatments for diabetics.

But the diabetes market has soured recently, with increasing competition squeezing prices, particularly in the United States, prompting the Danish group to warn last month that sales and profits might slip this year.

Novo Nordisk’s new CEO Lars Fruergaard Jorgensen, who took over in January, is under pressure to find new growth drivers for the group and he still has considerable financial firepower for “bolt-on” acquisitions in adjacent therapy areas.

Outside diabetes, Novo Nordisk already has a significant blood products business focused on hemophilia. However, its mainstay NovoSeven hemophilia drug could face challenges with
Roche’s new product ACE910 having the potential to erode sales.

Global Blood Therapeutics, which went public just two years ago, would offer a way diversify the Novo blood business and take it into new areas, including sickle cell disease and serious conditions in which the lungs cannot supply adequate oxygen to the blood.

The loss-making U.S. biotechnology company’s most advanced compound is GBT440, a once-daily pill for sickle cell disease that is in final-stage Phase III clinical testing.

Around 160,000 people suffer from sickle cell disease in the United States and Europe. Current treatments cost around $200,000 per year in the United States, and do not cure the disease.

Source: Reuters via CNBC

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.